The company reported encouraging Phase II data showing 77% disease control rate, durable survival beyond 20 months in a subset, and statistically significant improvements in PFS and OS with the induction strategy (HR 0.19; p=0.015). The immune activation and tumor microenvironment remodeling evidence supports further development, despite not meeting the primary ORR endpoint. The safety profile was consistent with component agents.
Company announced positive clinical trial progression with Phase II data presentation at major oncology conference (AACR 2026). The study demonstrates advancement in treating difficult-to-treat PD-1 refractory gastroesophageal cancer, representing a novel combination approach. Leadership commentary emphasizes potential for immune reprogramming and durable outcomes, suggesting confidence in the therapeutic approach and clinical development trajectory.
Articles that tag INKT but are mainly about other companies.
Developing off-the-shelf iNKT cell therapies with a lead candidate in Phase 2 trials and preliminary data expected H2 2026. However, the company faces similar capital constraints as GT Biopharma with ~$9.5 million cash and quarterly net losses of ~$2.7 million, indicating tight financial conditions.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
